Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical and Molecular Mechanism Study of Remimazolam Regulating the N/OFQ-inflammation-immune Axis to Optimize the Effect of General Anesthesia in Gynecological Surgery

NCT06990763 is registered in ClinicalTrials.gov with Second Hospital of Shanxi Medical University as lead sponsor.

NCT NCT06990763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06990763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical and Molecular Mechanism Study of Remimazolam Regulating the N/OFQ-inflammation-immune Axis to Optimize the Effect of General Anesthesia in Gynecological Surgery
Lead sponsor
Second Hospital of Shanxi Medical University
Phase
Not applicable
Overall status
Not yet recruiting
Start date
June 1, 2025
Completion date
January 1, 2026
Enrollment
40 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

gynecological disease